Related Experiment Video
Updated: Jul 28, 2026
11:49
Quantitative and Temporal Control of Oxygen Microenvironment at the Single Islet Level
Published on: November 17, 2013
Monotherapy with metformin: does it improve hypoxia in type 2 diabetic patients?
1Centre of Medical Biochemistry, Clinical Centre Nis, Yugoslavia. cosic@bankerinter.net
Clinical Chemistry and Laboratory Medicine
|October 17, 2001
Summary
Metformin therapy significantly reduced plasma xanthine oxidase (XO) activity and thiobarbituric acid-reactive substance (TBARS) levels in patients with type 2 diabetes. These findings suggest metformin may mitigate tissue damage by inhibiting XO.
Area of Science:
- Biochemistry
- Pharmacology
- Endocrinology
Background:
- Metformin is a primary treatment for type 2 diabetes, primarily inhibiting hepatic gluconeogenesis.
- The complete mechanisms of metformin action, including its broader physiological effects, remain incompletely understood.
- Diabetic patients exhibit increased free radical generation and thiobarbituric acid-reactive substance (TBARS) production, potentially linked to xanthine oxidase (XO).
Purpose of the Study:
- To investigate the impact of metformin on plasma xanthine oxidase (XO) activity, TBARS, lactate, fructosamine, and erythrocyte antioxidant enzyme activities in type 2 diabetes mellitus patients.
- To explore potential correlations between these biochemical markers and metformin treatment.
- To elucidate potential mechanisms by which metformin might reduce oxidative stress and tissue damage in diabetes.
Main Methods:
- A study involving 46 patients with type 2 diabetes mellitus undergoing metformin monotherapy.
- Simultaneous measurement of plasma XO activity, TBARS, lactate, fructosamine, and erythrocyte antioxidant enzymes before (T0), 1 month (T1), and 2 months (T2) after initiating metformin.
- Comparison of results with placebo and control groups.
Main Results:
- Metformin monotherapy led to a significant decrease in plasma XO activity and TBARS concentration compared to placebo and baseline (T0).
- A significant positive correlation was found between XO activity and fructosamine levels.
- Erythrocyte glutathione peroxidase activity showed a significant decrease at T2 compared to T0.
Conclusions:
- Metformin treatment significantly reduces plasma XO activity and TBARS levels in type 2 diabetes patients.
- The observed reduction in XO activity suggests a potential mechanism for metformin in mitigating oxidative stress and toxic tissue damage.
- Further research is warranted to fully understand the complex biochemical effects of metformin in diabetes management.
Related Concept Videos
01:36Carbohydrate Metabolism
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.